{"protocolSection":{"identificationModule":{"nctId":"NCT01974206","orgStudyIdInfo":{"id":"0113-CL-2001"},"secondaryIdInfos":[{"id":"2013-000464-29","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Astellas Pharma Inc","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-11-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-05-13","type":"ACTUAL"},"completionDateStruct":{"date":"2020-11-05","type":"ACTUAL"},"studyFirstSubmitDate":"2013-10-28","studyFirstSubmitQcDate":"2013-10-28","studyFirstPostDateStruct":{"date":"2013-11-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-10-21","resultsFirstSubmitQcDate":"2021-12-07","resultsFirstPostDateStruct":{"date":"2022-01-04","type":"ACTUAL"},"dispFirstSubmitDate":"2017-05-01","dispFirstSubmitQcDate":"2017-05-01","dispFirstPostDateStruct":{"date":"2017-05-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-15","lastUpdatePostDateStruct":{"date":"2024-10-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Astellas Pharma Global Development, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Vical","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study also evaluated the safety of ASP0113 in this patient population.","detailedDescription":"Participants were followed for one year after first study drug injection. This was the primary study period.\n\nParticipants were followed for 4.5 years after completion of the primary study to assess long-term safety of the vaccine."},"conditionsModule":{"conditions":["Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients"],"keywords":["ASP0113","Cytomegalovirus (CMV)","Kidney Transplantation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":150,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ASP0113","type":"EXPERIMENTAL","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).","interventionNames":["Biological: ASP0113"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"ASP0113","description":"intramuscular injection","armGroupLabels":["ASP0113"]},{"type":"DRUG","name":"Placebo","description":"intramuscular injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection","description":"CMV viremia was defined as presence of cytomegalovirus as measured in plasma viral load of ≥ 1000 IU/mL by central laboratory assay. A participant who discontinued the study without a positive CMV viral load was imputed as having a CMV viremia. A participant who had more than one viral load ≥ 1000 IU/mL by central assay was counted once in this summary. CMV viral loads after first injection (Day 1) through Day 380 (scheduled or unscheduled) were included in the analysis.","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Adjudicated CMV-Associated Disease, Including CMV Syndrome and CMV Tissue-Invasive Disease (Primary Study Period)","description":"An independent panel of medical experts reviewed/adjudicated events of CMV-associated disease including CMV syndrome and tissue invasive disease, which were defined according to the American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation 2006.","timeFrame":"From first study dose injection (day 1) up to one (up to Day 380) year post study drug injection"},{"measure":"Percentage of Participants With Plasma Viral Load ≥ The Lower Limit of Quantification (LLOQ) Assessed by Central Laboratory (Primary Study Period)","description":"The central laboratory had the LLOQ level for CMV viral load assessment. When the viral load was below the LLOQ the actual reading was not possible and was denoted as ≤LLOQ. If the participant had any CMV viral load assessments greater than the LLOQ, set up by the central laboratory, participant was classified as viremic and was included in the analysis.","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)"},{"measure":"Percentage of Participants Who Took Adjudicated CMV-specific Antiviral Therapy for the Treatment of CMV Viremia or Disease (Primary Study Period)","description":"An independent panel of medical experts reviewed/adjudicated events of CMV-specific AVT for treatment of CMV viremia or disease.","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)"},{"measure":"Percentage of Participants With Graft Survival (Primary Study Period)","description":"Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \\> 30 days). Missing values for graft survival were not included in the denominator when making the proportion. The analysis population was the FAS.","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)"},{"measure":"Percentage of Participants With Graft Survival (Long-term Follow up)","description":"Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \\> 30 days). Missing values for graft survival were not included in the denominator when making the proportion.","timeFrame":"Month 18, 30, 42, 54, and 66"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* CMV negative subject having received a CMV seropositive kidney (living or deceased)\n* Participant started valganciclovir or ganciclovir within 10 days of transplant and had received it through Randomization.\n\nExclusion Criteria:\n\n* Participant underwent a course of CMV-specific prophylactic therapy with antiviral drugs with a duration of greater than 100 days.\n* Participant had received from one month prior to transplant or planned to receive CMV immunoglobulin.\n* Participant had CMV viremia or CMV disease from time of transplant until time of Randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Astellas Pharma Global Development, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Site US10026","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Site US10003","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Site US10004","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Site US10036","city":"San Francisco","state":"California","zip":"94115","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Site US10037","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Site US10044","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Site US10018","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Site US10058","city":"Atlanta","state":"Georgia","zip":"30309","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Site US10013","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Site US10030","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Site US10009","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Site US10057","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Site US10046","city":"Lexington","state":"Kentucky","zip":"40536","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Site US10041","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Site US10049","city":"Portland","state":"Maine","zip":"04102","country":"United States","geoPoint":{"lat":43.65737,"lon":-70.2589}},{"facility":"Site US10023","city":"Ann Arbor","state":"Michigan","zip":"48109-5364","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Site US10048","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Site US10016","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Site US10015","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Site US10045","city":"Buffalo","state":"New York","zip":"14215","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Site US10012","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Site US10050","city":"Greenville","state":"North Carolina","zip":"27858","country":"United States","geoPoint":{"lat":35.61266,"lon":-77.36635}},{"facility":"Site US10001","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Site US10042","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Site US10047","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Site US10027","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Site US10028","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Site US10014","city":"Salt Lake City","state":"Utah","zip":"84132","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Site US10038","city":"Charlottesville","state":"Virginia","zip":"22903","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Site US10031","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Site US10020","city":"Seattle","state":"Washington","zip":"98101","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Site US10011","city":"Seattle","state":"Washington","zip":"98195-6175","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Site US10029","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Site AU61002","city":"Sydney","state":"New South Wales","zip":"NSW 2050","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Site AU61004","city":"Woolloongabba","state":"Queensland","zip":"QLD 4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Site AU61001","city":"Adelaide SA","state":"South Australia","zip":"5000","country":"Australia"},{"facility":"Site CA15004","city":"Vancouver","state":"British Columbia","zip":"V6Z 1Y6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Site CA15003","city":"Halifax","state":"Nova Scotia","zip":"B3H 1V8","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Site CA15005","city":"London","state":"Ontario","zip":"N6A 4V2","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Site CA15006","city":"Toronto","state":"Ontario","zip":"M5G2N2","country":"Canada","geoPoint":{"lat":43.65333,"lon":-79.38389}},{"facility":"Site FR33005","city":"Bordeaux","zip":"33000","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Site FR33003","city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Site FR33004","city":"Nantes","zip":"44000","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Site FR33001","city":"Nice","zip":"66001","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Site DE49002","city":"Berlin","zip":"10117","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Site DE49001","city":"Berlin","zip":"13353","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Site DE49008","city":"Bonn","zip":"53105","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"Site DE49003","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"Site DE49005","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Site ES34003","city":"Barcelona","zip":"08003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Site ES34002","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Site ES34001","city":"Barcelona","zip":"8907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Site ES34004","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}}]},"referencesModule":{"references":[{"pmid":"29745007","type":"DERIVED","citation":"Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 2018 Dec;18(12):2945-2954. doi: 10.1111/ajt.14925. Epub 2018 Jun 20."}],"seeAlsoLinks":[{"label":"Link to results and other applicable study documents on the Astellas Clinical Trials website","url":"https://www.clinicaltrials.astellas.com/study/?pid=0113-CL-2001"},{"label":"Link to plain language summary of the study on the Trial Results Summaries website","url":"https://www.trialsummaries.com/Study/StudyDetails?id=14616&tenant=MT_AST_9011"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.","accessCriteria":"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.","url":"https://www.clinicaltrials.astellas.com/transparency/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Screening assessments were performed from 14-30 days after the transplant. Participants were randomized at day 30 in relation to the day of the transplant, in a 1:1 ratio to ASP0113 or placebo. Participants were stratified by the use of antithymocyte globulin (ATG) prior to randomization and by the receipt of a kidney from a living or deceased donor.","recruitmentDetails":"A total of 150 participants were enrolled into the study from 6 countries. Eligible participants were ≥18 years of age, CMV-seronegative at the time of the transplant and had a kidney allograft from a CMV-seropositive living or deceased donor. After the primary period completion, 149 participants entered the long-term follow-up period.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"FG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"76"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"75"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"75"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Did Not Take Study Drug","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized population: Age, Gender, Race, Ethnicity Randomized population: Use of ATG, Source of current Transplant, randomization strata","groups":[{"id":"BG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"BG001","title":"ASP0113","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"150"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47.9","spread":"13.3"},{"groupId":"BG001","value":"50.8","spread":"13.6"},{"groupId":"BG002","value":"49.4","spread":"13.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"40"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"110"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"72"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"78"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"118"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Use of ATG","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"No","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"88"}]},{"title":"Yes","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"62"}]}]}]},{"title":"Randomization Strata","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Living Donor & ATG Use = No","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]},{"title":"Living Donor & ATG Use = Yes","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]},{"title":"Deceased Donor & ATG Use = Yes","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"44"}]},{"title":"Deceased Donor & ATG Use = No","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"53"}]},{"title":"Not Recorded","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Source of Current Transplant","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"LIVING UNRELATED DONOR","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"27"}]},{"title":"LIVING RELATED DONOR","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"25"}]},{"title":"DECEASED DONOR","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"97"}]},{"title":"Not Recorded","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection","description":"CMV viremia was defined as presence of cytomegalovirus as measured in plasma viral load of ≥ 1000 IU/mL by central laboratory assay. A participant who discontinued the study without a positive CMV viral load was imputed as having a CMV viremia. A participant who had more than one viral load ≥ 1000 IU/mL by central assay was counted once in this summary. CMV viral loads after first injection (Day 1) through Day 380 (scheduled or unscheduled) were included in the analysis.","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least 1 dose of randomized study drug and who had at least 1 post dose viral load assessment within 1 year post first injection by central laboratory.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Paticipants","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"title":"Known CMV viremia","categories":[{"measurements":[{"groupId":"OG000","value":"35.6"},{"groupId":"OG001","value":"35.6"}]}]},{"title":"Imputed CMV viremia due to discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"5.5"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Cochran-Mantel-Haenszel (CMH) estimate of the common odds ratio (ASP0113 vs placebo) stratified by randomization strata, and the 90% CIs of the CMH odds ratio stratified by randomization group.","nonInferiorityType":"OTHER","pValue":"0.307","pValueComment":"P-value (1-sided) of the Exact Cochran-Mantel-Haenszel method adjusted odds ratio stratified by randomization group.","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Common Odds Ratio","paramValue":"0.79","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.43","ciUpperLimit":"1.47"}]},{"type":"SECONDARY","title":"Percentage of Participants With Adjudicated CMV-Associated Disease, Including CMV Syndrome and CMV Tissue-Invasive Disease (Primary Study Period)","description":"An independent panel of medical experts reviewed/adjudicated events of CMV-associated disease including CMV syndrome and tissue invasive disease, which were defined according to the American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation 2006.","populationDescription":"The analysis population was the FAS.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"From first study dose injection (day 1) up to one (up to Day 380) year post study drug injection","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.18"},{"groupId":"OG001","value":"19.18"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The exact Cochran-Mantel-Haenszel (CMH) estimate of the common odds ratio (ASP0113 vs placebo) stratified by randomization group, and the 90% CI of the exact CMH odds ratio stratified by randomization group.","nonInferiorityType":"OTHER","pValue":"0.576","pValueComment":"P-value (1-sided) of the Exact Cochran-Mantel-Haenszel method adjusted odds ratio stratified by randomization group.","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Common Odds Ratio","paramValue":"0.99","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"2.15"}]},{"type":"SECONDARY","title":"Percentage of Participants With Plasma Viral Load ≥ The Lower Limit of Quantification (LLOQ) Assessed by Central Laboratory (Primary Study Period)","description":"The central laboratory had the LLOQ level for CMV viral load assessment. When the viral load was below the LLOQ the actual reading was not possible and was denoted as ≤LLOQ. If the participant had any CMV viral load assessments greater than the LLOQ, set up by the central laboratory, participant was classified as viremic and was included in the analysis.","populationDescription":"The analysis population was the FAS.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.32"},{"groupId":"OG001","value":"46.58"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The exact Cochran-Mantel-Haenszel (CMH) estimate of the common odds ratio (ASP0113 vs placebo) stratified by randomization group, and the 90% CI of the exact CMH odds ratio stratified by randomization group.","nonInferiorityType":"OTHER","pValue":"0.408","pValueComment":"P-value (1-sided) of the Exact Cochran-Mantel-Haenszel method adjusted odds ratio stratified by randomization group.","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Common Odds Ratio","paramValue":"0.88","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"1.59"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Took Adjudicated CMV-specific Antiviral Therapy for the Treatment of CMV Viremia or Disease (Primary Study Period)","description":"An independent panel of medical experts reviewed/adjudicated events of CMV-specific AVT for treatment of CMV viremia or disease.","populationDescription":"The analysis population was the FAS.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.21"},{"groupId":"OG001","value":"42.47"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The exact Cochran-Mantel-Haenszel (CMH) estimate of the common odds ratio (ASP0113 vs placebo) stratified by randomization group, and the 90% CI of the exact CMH odds ratio stratified by randomization group.","nonInferiorityType":"OTHER","pValue":"0.419","pValueComment":"P-value (1-sided) of the Exact Cochran-Mantel-Haenszel method adjusted odds ratio stratified by randomization group.","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Common Odds Ratio","paramValue":"0.88","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"1.61"}]},{"type":"SECONDARY","title":"Percentage of Participants With Graft Survival (Primary Study Period)","description":"Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \\> 30 days). Missing values for graft survival were not included in the denominator when making the proportion. The analysis population was the FAS.","populationDescription":"The analysis population was the FAS, with data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"From first study dose injection (day 1) up to one year post study drug injection (up to Day 380)","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.53"},{"groupId":"OG001","value":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Exact Cochran-Mantel-Haenszel estimate of the common odds ratio could not be calculated as 100% of ASP0113 group showed graft survival, and this leads to having a value of 0 for the denominator for the ratio thus odds ratio is not estimable. The 90% CI (2-sided) values for the odds ratio are 0.11 to NA, where NA is an infinity value.","nonInferiorityType":"OTHER","pValue":"0.5","pValueComment":"P-value (1-sided) of the Exact Cochran-Mantel-Haenszel method adjusted odds ratio stratified by randomization group.","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Percentage of Participants With Graft Survival (Long-term Follow up)","description":"Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \\> 30 days). Missing values for graft survival were not included in the denominator when making the proportion.","populationDescription":"All participants who entered long-term follow-up.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Month 18, 30, 42, 54, and 66","groups":[{"id":"OG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."},{"id":"OG001","title":"ASP0113 5mg","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"76"}]}],"classes":[{"title":"Long Term Follow Up Month 18","categories":[{"measurements":[{"groupId":"OG000","value":"91.9"},{"groupId":"OG001","value":"94.7"}]}]},{"title":"Long Term Follow Up Month 30","categories":[{"measurements":[{"groupId":"OG000","value":"83.8"},{"groupId":"OG001","value":"81.6"}]}]},{"title":"Long Term Follow Up Month 42","categories":[{"measurements":[{"groupId":"OG000","value":"85.1"},{"groupId":"OG001","value":"80.3"}]}]},{"title":"Long Term Follow Up Month 54","categories":[{"measurements":[{"groupId":"OG000","value":"78.4"},{"groupId":"OG001","value":"77.6"}]}]},{"title":"Long Term Follow Up Month 66","categories":[{"measurements":[{"groupId":"OG000","value":"82.4"},{"groupId":"OG001","value":"84.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 1 to Day 380","description":"Treatment Emergent Adverse Event (TEAE) was defined as an adverse event observed after the first study drug injection Day 1 through Day 380. No AEs were collected / reported during the long-term follow-up period.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).","deathsNumAffected":5,"deathsNumAtRisk":74,"seriousNumAffected":36,"seriousNumAtRisk":74,"otherNumAffected":72,"otherNumAtRisk":74},{"id":"EG001","title":"ASP0113","description":"Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).","deathsNumAffected":7,"deathsNumAtRisk":75,"seriousNumAffected":44,"seriousNumAtRisk":75,"otherNumAffected":75,"otherNumAtRisk":75}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hyperparathyroidism tertiary","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Angle closure glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Aphthous stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Gastrointestinal toxicity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Kidney transplant rejection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Abscess soft tissue","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"BK virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":75}]},{"term":"Bacterial pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cytomegalovirus colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":75}]},{"term":"Cytomegalovirus mucocutaneous ulcer","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":75}]},{"term":"Cytomegalovirus oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cytomegalovirus syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Cytomegalovirus viraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":75}]},{"term":"Enterococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Enterocolitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Epstein-Barr viraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":75}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Gastroenteritis clostridial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Haematoma infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infected lymphocele","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pneumocystis jiroveci pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Pneumonia cytomegaloviral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Polyomavirus-associated nephropathy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Streptococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":75}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":75}]},{"term":"Urinary tract infection enterococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urinary tract infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Bone fissure","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Graft haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Graft thrombosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Perinephric collection","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":75}]},{"term":"Post procedural haematuria","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Seroma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"HLA marker study positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Immunosuppressant drug level increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":75}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Colorectal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Invasive lobular breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Metastases to peritoneum","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":75}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Calculus urinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Renal artery stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":75}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Renal tubular necrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Ureteric stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urinary bladder atrophy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urinary tract disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urinoma","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Nephrectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Transurethral prostatectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Ureteral stent removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Urostomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Lymphocele","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":75}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":74},{"groupId":"EG001","numEvents":32,"numAffected":29,"numAtRisk":75}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":75}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":75}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":24,"numAtRisk":74},{"groupId":"EG001","numEvents":33,"numAffected":23,"numAtRisk":75}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":75}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":74},{"groupId":"EG001","numEvents":22,"numAffected":13,"numAtRisk":75}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":74},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":75}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":24,"numAtRisk":74},{"groupId":"EG001","numEvents":59,"numAffected":27,"numAtRisk":75}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":14,"numAffected":8,"numAtRisk":75}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":18,"numAtRisk":74},{"groupId":"EG001","numEvents":277,"numAffected":47,"numAtRisk":75}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":75}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":75}]},{"term":"BK virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":74},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":75}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":75}]},{"term":"Cytomegalovirus syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":75}]},{"term":"Cytomegalovirus viraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":74},{"groupId":"EG001","numEvents":30,"numAffected":22,"numAtRisk":75}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":75}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":75}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":74},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":75}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":17,"numAffected":10,"numAtRisk":75}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":75}]},{"term":"Complications of transplant surgery","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Complications of transplanted kidney","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":75}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":74},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":75}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":75}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":13,"numAffected":7,"numAtRisk":75}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":75}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":74},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":75}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":75}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":75}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":75}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":75}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":4,"numAtRisk":75}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":15,"numAtRisk":74},{"groupId":"EG001","numEvents":38,"numAffected":21,"numAtRisk":75}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":75}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":74},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":75}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":75}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":75}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":75}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":74},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":75}]},{"term":"Kidney fibrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":75}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":75}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":75}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Ureteral stent removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":74},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":74},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":75}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":74},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":75}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":74},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":75}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement."},"pointOfContact":{"title":"Clinical Trial Disclosure","organization":"Astellas Pharma Global Development, Inc.","email":"astellas.resultsdisclosure@astellas.com","phone":"800-888-7704"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2014-01-06","uploadDate":"2021-10-21T11:08","filename":"Prot_000.pdf","size":3683290},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2016-07-28","uploadDate":"2021-10-21T11:08","filename":"SAP_001.pdf","size":352603}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}